Clinical Trial Update: Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial [Phase 2]

View source ↗

Summary

A phase 2 clinical trial (EMILIA) is evaluating daratumumab as maintenance therapy to improve survival in patients with AL amyloidosis; the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Mayo Clinic | Conditions: AL Amyloidosis | Phase 2 | Status: RECRUITING